Ewing’s sarcoma metastatic – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:13:48 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Ewing’s sarcoma metastatic – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma https://clinicaltrials.eu/trial/study-on-chemotherapy-with-gemcitabine-lenvatinib-and-temozolomide-for-patients-with-recurrent-and-primary-refractory-ewing-sarcoma/ Wed, 29 Apr 2026 15:02:19 +0000 https://clinicaltrials.eu/trial/study-on-chemotherapy-with-gemcitabine-lenvatinib-and-temozolomide-for-patients-with-recurrent-and-primary-refractory-ewing-sarcoma/ This clinical trial focuses on treating patients with Ewing Sarcoma that has either come back after treatment or did not respond to initial treatment. The study tests several chemotherapy medications including gemcitabine, docetaxel, irinotecan, temozolomide, topotecan, carboplatin, cyclophosphamide, ifosfamide, etoposide, and lenvatinib. The purpose is to determine which treatment combination works best in terms of effectiveness and side effects.

The treatment involves different combinations of these medications given either through an intravenous infusion into a vein or as oral capsules taken by mouth. Some medications are given daily while others are administered on specific days during treatment cycles that typically last several weeks. The total treatment duration may continue for up to 104 weeks depending on how well the treatment works.

Throughout the study, doctors will monitor the size of tumors using imaging scans to check if the treatment is working. They will also track any side effects and how long patients stay in the hospital. The study measures how long patients live without their disease getting worse and their overall survival time. Additionally, patients’ quality of life will be evaluated during the treatment period.

]]> Study on the Effectiveness and Safety of Regorafenib for Patients with Resistant Primary Bone Tumors https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-regorafenib-for-patients-with-resistant-primary-bone-tumors/ Wed, 29 Apr 2026 15:00:58 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-regorafenib-for-patients-with-resistant-primary-bone-tumors/ This clinical trial is focused on studying the effects of a medication called Regorafenib on patients with a type of cancer known as refractory primary bone tumors. These tumors are a form of cancer that originates in the bones and have not responded to previous treatments. The purpose of the study is to evaluate how effective and safe Regorafenib is for these patients.

Participants in the study will take Regorafenib in the form of a film-coated tablet, which is taken orally. The study will monitor patients over a period to see how the medication affects their condition. This includes observing any changes in the tumor, as well as any side effects that may occur. The study aims to determine if Regorafenib can help control the disease and improve the quality of life for patients.

Throughout the study, various health checks will be conducted, such as laboratory tests and heart monitoring, to ensure the safety of the participants. The study will also look at how the body processes the medication, including how long it takes to reach a steady level in the bloodstream. This information will help researchers understand the best way to use Regorafenib in treating refractory primary bone tumors.

]]> Study on the Effectiveness and Safety of Regorafenib for Patients with Metastatic Bone Sarcomas https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-regorafenib-for-patients-with-metastatic-bone-sarcomas/ Wed, 29 Apr 2026 15:00:51 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-regorafenib-for-patients-with-metastatic-bone-sarcomas/ This clinical trial is focused on studying the effects of a medication called regorafenib in patients with a type of cancer known as metastatic bone sarcoma. Metastatic bone sarcoma is a cancer that starts in the bones and can spread to other parts of the body. The purpose of the study is to evaluate how well regorafenib works in treating this condition and to assess its safety for patients.

Participants in the study will receive either regorafenib or a placebo, which is a substance with no active medication. The study will take place over several months, during which patients will be monitored regularly to see how their cancer responds to the treatment. This will involve various assessments, including imaging tests like MRI or CT scans, to track changes in the cancer. The study aims to determine if regorafenib can help control the cancer and improve the patients’ quality of life.

Throughout the study, patients will be closely observed for any side effects or changes in their condition. The information gathered will help researchers understand the potential benefits and risks of using regorafenib for treating metastatic bone sarcoma. This research is important for developing new treatment options for patients with this challenging type of cancer.

]]> Study of Regorafenib with Chemotherapy for Newly Diagnosed Patients with Metastatic Ewing Sarcoma https://clinicaltrials.eu/trial/study-of-regorafenib-with-chemotherapy-for-newly-diagnosed-patients-with-metastatic-ewing-sarcoma/ Wed, 29 Apr 2026 14:23:42 +0000 https://clinicaltrials.eu/trial/study-of-regorafenib-with-chemotherapy-for-newly-diagnosed-patients-with-metastatic-ewing-sarcoma/ This clinical trial is focused on studying a type of cancer called Ewing sarcoma, which is a rare cancer that affects bones or the soft tissue around bones. The study is specifically for patients who have been newly diagnosed with Ewing sarcoma that has spread to other parts of the body, except for the lungs or the lining around the lungs. The treatment being tested in this study is a combination of a drug called regorafenib and standard chemotherapy. Regorafenib is a medication that is taken by mouth and is being tested in two forms: as granules and as film-coated tablets. The purpose of the study is to find the best dose of regorafenib when used with chemotherapy for treating this type of cancer.

Participants in the study will receive the combination of regorafenib and chemotherapy. The study will monitor how the body responds to the treatment and any side effects that may occur. The study will also look at how the cancer responds to the treatment, including whether it shrinks or stops growing. The study will last for several years, and participants will be closely monitored throughout the process to ensure their safety and to gather important information about the treatment’s effectiveness.

The study aims to improve the treatment options for patients with Ewing sarcoma by determining the most effective way to use regorafenib in combination with chemotherapy. This research could potentially lead to better outcomes for patients with this challenging form of cancer. Participants will be contributing to important research that may help future patients with Ewing sarcoma.

]]>